Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIOGEN INC.

(BIIB)
  Rapport
Vertraagde tijd Nasdaq  -  22:00 29-09-2022
264.28 USD   -4.46%
29/09Biogen Inc. : Oppenheimer herhaalt koopadvies voor het aandeel
MM
29/09Japanse Nikkei volgt Wall Street hoger bij dalende rente op staatsobligaties
MR
28/09Amerikaanse aandelen stijgen woensdag, rente daalt na beweging Bank of England
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť BIOGEN INC.
28/09Biogen, Thor rise; Apple, Equitrans Midstream fall
AQ
28/09Eisai - lecanemab confirmatory phase 3 clarity ad study met primary endpoint, showing h..
AQ
28/09Update1 : Alzheimer's drug proves effective in slowing symptoms, says Eisai
AQ
28/09Alzheimer's drug proves effective in slowing symptoms, says Eisai
AQ
27/09Statement : Biogen Statement On Qui Tam Settlement
PU
22/09University Of Sheffield : Promising MND drug helps slow disease progression and benefits p..
AQ
21/09The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits ..
GL
21/09The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits ..
GL
20/09Statement : Biogen completes corporate real estate transaction to align its cambridge offi..
PU
19/09Tysabriģ (Natalizumab) Litigation Begins
AQ
07/09The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phas..
GL
31/08Biogen : to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
PU
31/08Biogen : Statement on Alzheimer's & Dementiaģ Journal Publication about Association betwee..
PU
04/08Eisai presents new findings on lecanemab's investigational subcutaneous formulation and..
PR
28/07The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BII..
GL
28/07The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BII..
AQ
27/07Biogen Inc. - FDA Accepts Biogen's New Drug Application and Grants Priority Review of T..
AQ
26/07FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a ..
GL
20/07BIOGEN INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
20/07Biogen : Reports Second Quarter 2022 Results - Form 8-K/A
PU
20/07Biogen chops expenses in Q2, raises 2022 profit forecast
AQ
20/07Biogen : Reports Second Quarter 2022 Results 582.7 KB
PU
20/07Biogen : Reports Second Quarter 2022 Results
PU
20/07Biogen : Reports Second Quarter 2022 Results - Form 8-K
PU
20/07Biogen : Q2 2022 Biogen Earnings Presentation
PU
20/07Biogen : Reports Q2 2022 Earnings
PU
06/07Biogen : to Report Second Quarter 2022 Financial Results July 20, 2022
PU
06/07Eisai Co., Ltd. - THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS..
AQ
06/07The u.s. fda accepts and grants priority review for eisai's biologics license applicati..
PR
22/06Biogen Inc. - European Patent Office Grants Patent Related to TECFIDERA (Dimethyl Fumar..
AQ
22/06Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital..
BU
21/06Biogen Inc. : Change in Directors or Principal Officers, Submission of Matters to a Vote o..
AQ
21/06European Patent Office Grants Patent Related to TECFIDERAģ (Dimethyl Fumarate)
GL
16/06Biogen Inc. - New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA P..
AQ
15/06Biogen : Annual Stockholder Presentation 2022
PU
15/06Biogen : Appreciation Statement for Retiring Board Members Nancy Leaming and Brian Posner
PU
15/06New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treate..
GL
15/06New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treate..
AQ
14/06The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities
GL
08/06Biogen And Samsung Bioepis Launch BYOOVIZ (ranibizumab-nuna)
AQ
08/06Biogen : Withdrawal from the Jefferies Healthcare Conference
PU
06/06Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar..
AQ
06/06Biogen Inc. - New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Me..
AQ
06/06Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL0181..
GL
06/06Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL0181..
AQ
03/06Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar..
GL
03/06Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar..
AQ
03/06New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benef..
GL
03/06New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benef..
AQ
02/06Biogen and Samsung Bioepis' BYOOVIZ™ (ranibizumab-nuna) Launches in the United St..
AQ
31/05Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor..
AQ
27/05Biogen : to Participate in the Jefferies Healthcare Conference
PU
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
BU
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
GL
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
AQ
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
03/05BIOGEN INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
03/05Change at the top for Biogen after Alzheimer's drug flops
AQ
03/05Biogen Inc. : Results of Operations and Financial Condition, Change in Directors or Princi..
AQ
03/05Biogen : Reports First Quarter 2022 Results
PU
03/05Biogen : Q1 2021 Biogen Earnings Presentation
PU
30/04Biogen : Statement Regarding Updated ADUHELMģ (aducanumab-avwa) Prescribing Information in..
PU
28/04Samsung Biologics Completes Full Acquisition Of Samsung Bioepis
AQ
22/04Biogen : Update on Regulatory Submission for Aducanumab in the European Union
PU
20/04Biogen : Completes Sale of Equity Stake in Biosimilar Joint Venture to Samsung Biologics f..
PU
08/04Biogen : Statement on the Final National Coverage Determination for Amyloid-Beta Targeting..
PU
05/04Biogen : to Report First Quarter 2022 Financial Results May 3, 2022
PU
04/04New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerg..
AQ
30/03Biogen Submits Final Protocol for ADUHELMģ (aducanumab-avwa) Phase 4 ENVISION Trial to ..
AQ
28/03Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9or..
AQ
23/03Eisai Co., Ltd - LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKE..
AQ
22/03Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship t..
AQ
18/03Biogen : The National Minority Quality Forum and Biogen Highlight Equitable Access to Rese..
PU
17/03Biogen : to Participate in the Stifel 2022 CNS Days
PU
17/03Biogen Announces Peer-Reviewed Publication of ADUHELM Phase 3 EMERGE and ENGAGE Data in..
AQ
1  2  3  4  5  6  7  8  9  10Volgende
Volgende evenement op BIOGEN INC.